Drug Imports Risk Medical Research

President Obama has urged lawmakers to legalize the importation of prescription drugs from abroad. Advocates claim importation would lower drug costs by giving Americans access to the cheaper medicines available overseas.

In truth, though, drug importation would harm Americans' health and jeopardize future developments in medical science.

Many countries don't adhere to the same rigorous safety standards as the United States. So there's a serious danger that foreign drugs are counterfeit or poorly produced. Africa and Asia are ground-zero for the counterfeit trade. For example, a 2002 study in Senegal found that 21 of 22 samples of ampicillin, the common antibiotic, contained only flour.

Third World counterfeits often make their way to First World shores.

Third World counterfeits often make their way to First World shores. Europe's system of "parallel trade" allows drugs to freely cross borders. Middlemen in each country can open and repackage drug shipments before sending them along. Such a system makes it easier for counterfeits to enter the supply chain. Last year, European officials seized more than 34 million fake pills in just two months.

Tracking and scanning technology is improving, though, as is supply-chain management. So regulators may one day be able to protect consumers. But even then, importation will be a flawed policy.

Canadians and Europeans pay less for certain brand-name drugs because their governments impose price controls. If a drug company refuses to sell at the price the government demands, then the government often threatens to break the company's patent. By importing these drugs, Americans would effectively be importing price controls. This would hamstring medical research.

Developing a new drug is costly. On average, it takes 15 years and $1.3 billion to bring a new drug to market. For every 10,000 compounds tested, only five ever make it to clinical trial. Of those five, only one is ever approved. By paying higher prices for brand-name drugs, Americans bankroll the lion's share of these research efforts. This isn't fair, but it's reality.

Rather than impose backdoor price controls through importation, U.S. lawmakers should pressure foreign governments to relax their price controls and shoulder more of the research burden.

Legalized drug importation has long seduced politicians and consumers alike. But its negative consequences for patient safety and pharmaceutical research are too significant to ignore.

Roger Bate is the Legatum Fellow in Global Prosperity at AEI.

Also Visit
AEIdeas Blog The American Magazine
About the Author

 

Roger
Bate
  • Roger Bate is an economist who researches international health policy, with a particular focus on tropical disease and substandard and counterfeit medicines. He also writes on general development policy in Asia and Africa. He writes regularly for AEI's Health Policy Outlook.
  • Phone: 202-828-6029
    Email: rbate@aei.org
  • Assistant Info

    Name: Katherine Earle
    Phone: (202) 862-5872
    Email: katherine.earle@aei.org

What's new on AEI

image Dad and the diploma: The difference fathers make for college graduation
image A better way to finance that college degree
image Fracking for bigger budgets
image Earth Day: Hail fossil fuels, energy of the future
AEI on Facebook
Events Calendar
  • 21
    MON
  • 22
    TUE
  • 23
    WED
  • 24
    THU
  • 25
    FRI
Wednesday, April 23, 2014 | 12:00 p.m. – 1:30 p.m.
Graduation day: How dads’ involvement impacts higher education success

Join a diverse group of panelists — including sociologists, education experts, and students — for a discussion of how public policy and culture can help families lay a firmer foundation for their children’s educational success, and of how the effects of paternal involvement vary by socioeconomic background.

Thursday, April 24, 2014 | 12:00 p.m. – 1:30 p.m.
Getting it right: A better strategy to defeat al Qaeda

This event will coincide with the release of a new report by AEI’s Mary Habeck, which analyzes why current national security policy is failing to stop the advancement of al Qaeda and its affiliates and what the US can do to develop a successful strategy to defeat this enemy.

Friday, April 25, 2014 | 9:15 a.m. – 1:15 p.m.
Obamacare’s rocky start and uncertain future

During this event, experts with many different views on the ACA will offer their predictions for the future.   

No events scheduled this day.
No events scheduled this day.
No events scheduled this day.
No events scheduled this day.
No events scheduled this day.